{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:44:05Z","timestamp":1790102645885,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.canep.2013.09.001","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T01:51:57Z","timestamp":1380073917000},"page":"881-885","source":"Crossref","is-referenced-by-count":89,"title":["Antihypertensive medications and survival in patients with cancer: A population-based retrospective cohort study"],"prefix":"10.1016","volume":"37","author":[{"given":"Signy","family":"Holmes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Jane","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald Y.","family":"Minuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"April (4)","key":"10.1016\/j.canep.2013.09.001_bib0005","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/HJH.0b013e3282f3ef5e","article-title":"Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials","volume":"26","author":"Coleman","year":"2008","journal-title":"J Hypertens"},{"issue":"August (9281)","key":"10.1016\/j.canep.2013.09.001_bib0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(01)05704-X","article-title":"Relation between drug treatment and cancer in hypertensives in the Swedish trial in old patients with hypertension 2: a 5-year, prospective, randomized, controlled trial","volume":"358","author":"Lindholm","year":"2001","journal-title":"Lancet"},{"issue":"July\u2013August (5\u20136)","key":"10.1016\/j.canep.2013.09.001_bib0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3109\/10641969909061022","article-title":"Is cancer related to hypertension or to its treatment?","volume":"21","author":"Lever","year":"1999","journal-title":"Clin Exp Hypertens"},{"issue":"November (9)","key":"10.1016\/j.canep.2013.09.001_bib0020","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L","article-title":"Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark","volume":"92","author":"Friis","year":"2001","journal-title":"Cancer"},{"issue":"January (1)","key":"10.1016\/j.canep.2013.09.001_bib0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004872-199816010-00017","article-title":"Cancer risk of hypertensive patients taking calcium antagonists","volume":"16","author":"Hole","year":"1998","journal-title":"J Hypertens"},{"issue":"July (7)","key":"10.1016\/j.canep.2013.09.001_bib0030","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00004872-199816070-00006","article-title":"Hypertension and long-term cancer incidence and mortality among Swedish men","volume":"16","author":"Rosengren","year":"1998","journal-title":"J Hypertens"},{"issue":"July (7)","key":"10.1016\/j.canep.2013.09.001_bib0035","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/00004872-199816070-00007","article-title":"Hypertension, antihypertensive drugs, and mortality from cancer among women","volume":"16","author":"Peeters","year":"1998","journal-title":"J Hypertens"},{"key":"10.1016\/j.canep.2013.09.001_bib0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1024491219366","article-title":"Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells","volume":"80","author":"Drell","year":"2003","journal-title":"Breast Cancer Res Treat"},{"issue":"June (11)","key":"10.1016\/j.canep.2013.09.001_bib0045","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/ijc.21723","article-title":"The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB\/c nude mice is inhibited by \u03b2-blockers","volume":"118","author":"Palm","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canep.2013.09.001_bib0050","first-page":"2866","article-title":"Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers","volume":"61","author":"Masur","year":"2001","journal-title":"Cancer Res"},{"issue":"April (4)","key":"10.1016\/j.canep.2013.09.001_bib0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0714.2008.00691.x","article-title":"Expression of beta2-adrenergic receptor in oral squamous cell carcinoma","volume":"38","author":"Shang","year":"2009","journal-title":"J Oral Pathol Med"},{"issue":"February (4)","key":"10.1016\/j.canep.2013.09.001_bib0060","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/cncr.23231","article-title":"GABAB receptor is a novel drug target for pancreatic cancer","volume":"112","author":"Schuller","year":"2008","journal-title":"Cancer"},{"issue":"September (9)","key":"10.1016\/j.canep.2013.09.001_bib0065","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","article-title":"The renin-angiotensin system and malignancy","volume":"29","author":"Ager","year":"2008","journal-title":"Carcinogenesis"},{"issue":"June (2)","key":"10.1016\/j.canep.2013.09.001_bib0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0006-291X(02)00496-5","article-title":"Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis","volume":"294","author":"Fujita","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"May (10)","key":"10.1016\/j.canep.2013.09.001_bib0075","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2093::AID-CNCR1>3.0.CO;2-E","article-title":"Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential","volume":"85","author":"Mason","year":"1999","journal-title":"Cancer"},{"issue":"December (6)","key":"10.1016\/j.canep.2013.09.001_bib0080","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2170\/physiolsci.RP010806","article-title":"Furosemide, a blocker of Na+\/K+\/2CI\u2212 cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0\/G1 state","volume":"56","author":"Shiozaki","year":"2006","journal-title":"J Physiol Sci"},{"issue":"March (11)","key":"10.1016\/j.canep.2013.09.001_bib0085","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1073\/pnas.0712345105","article-title":"Comparative lesion sequencing provides insights into tumor evolution","volume":"105","author":"Jones","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"February (3)","key":"10.1016\/j.canep.2013.09.001_bib0100","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.toxlet.2009.11.018","article-title":"L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines","volume":"192","author":"Chiu","year":"2010","journal-title":"Toxicol Lett"},{"issue":"November (9)","key":"10.1016\/j.canep.2013.09.001_bib0105","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<2003::AID-CNCR17>3.0.CO;2-3","article-title":"Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses\u2019 health study","volume":"83","author":"Michels","year":"1998","journal-title":"Cancer"},{"issue":"January (1)","key":"10.1016\/j.canep.2013.09.001_bib0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol"},{"issue":"November (11)","key":"10.1016\/j.canep.2013.09.001_bib0115","first-page":"678","article-title":"Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care","volume":"12","author":"Taira","year":"2006","journal-title":"Am J Manag Care"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782113001422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782113001422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T04:08:42Z","timestamp":1716005322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782113001422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1877782113001422"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2013.09.001","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}